The cost of conducting the required pediatric studies is typically $30 million to $100 million a return-on-investment that makes pediatric exclusivity one of the clearest value-creation opportunities in pharmaceutical development
Lovblad KO, Baird AE, Schlaug G, Benfield A, Siewert B, Voetsch B, et al: Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome
The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend against using compounded testosterone preparations unless commercial products are not available or not appropriate for the patient." [12] That "unless" clause covers a meaningful subset of patients, but the default should be commercial product first
Instead, this is a safe, well-researched, doctor-approved weight reduction therapy, unlike any other
Probabilistic environmental risk characterization of pharmaceuticals in sewage treatment plant discharges
The probe holders allow for a +/- 1/2 inch elevation adjustment
